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Mutation in the Plasmodium falciparum CRT Protein Determines the
Stereospecific Activity of Antimalarial Cinchona Alkaloids
Carol E. Grifﬁn,a* Jonathan M. Hoke,a Upeka Samarakoon,b Junhui Duan,c Jianbing Mu,c Michael T. Ferdig,b David C. Warhurst,d
and Roland A. Coopera,e
Department of Biological Sciences, Old Dominion University, Norfolk, Virginia, USAa; Eck Institute for Global Health, Department of Biological Sciences, University of Notre
Dame, South Bend, Indiana, USAb; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville,
Maryland, USAc; Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, United
Kingdomd; and Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USAe

The Cinchona alkaloids are quinoline aminoalcohols that occur as diastereomer pairs, typified by (ⴚ)-quinine and (ⴙ)-quinidine. The potency of (ⴙ)-isomers is greater than the (ⴚ)-isomers in vitro and in vivo against Plasmodium falciparum malaria
parasites. They may act by the inhibition of heme crystallization within the parasite digestive vacuole in a manner similar to
chloroquine. Earlier studies showed that a K76I mutation in the digestive vacuole-associated protein, PfCRT (P. falciparum
chloroquine resistance transporter), reversed the normal potency order of quinine and quinidine toward P. falciparum. To further explore PfCRT-alkaloid interactions in the malaria parasite, we measured the in vitro susceptibility of eight clonal lines of
P. falciparum derived from the 106/1 strain, each containing a unique pfcrt allele, to four Cinchona stereoisomer pairs: quinine
and quinidine; cinchonidine and cinchonine; hydroquinine and hydroquinidine; 9-epiquinine and 9-epiquinidine. Stereospecific potency of the Cinchona alkaloids was associated with changes in charge and hydrophobicity of mutable PfCRT amino acids. In isogenic chloroquine-resistant lines, the IC50 ratio of (ⴚ)/(ⴙ) CA pairs correlated with side chain hydrophobicity of the
position 76 residue. Second-site PfCRT mutations negated the K76I stereospecific effects: charge-change mutations C72R or
Q352K/R restored potency patterns similar to the parent K76 line, while V369F increased susceptibility to the alkaloids and nullified stereospecific differences between alkaloid pairs. Interactions between key residues of the PfCRT channel/transporter with
(ⴚ) and (ⴙ) alkaloids are stereospecifically determined, suggesting that PfCRT binding plays an important role in the antimalarial activity of quinine and other Cinchona alkaloids.

A

lkaloids from the Cinchona tree, exemplified by quinine (QN)
and quinidine (QD), have proven to be an important source
of antimalarial therapies, especially after resistance to chloroquine
(CQ) emerged. QN remains a first-line drug in the treatment of
severe malaria in many parts of the world, even with increased use
of artemisinin-based combination therapies (70). The Cinchona
alkaloids (CA) are aryl amino alcohols where the aryl group is a
quinoline (quinoline aminoalcohols). They have four chiral centers, two of which, C-8 and C-9, can have different configurations
(66) (Fig. 1). Among the pharmacologically active 8,9-erythro isomers, QN, hydroquinine (HQN), and cinchonidine (CD) all present the S configuration around C-8 and the R configuration at C-9
and are levorotatory (rotate plane polarized light in an anticlockwise [⫺] direction). The reverse ordering, R at C-8 and S at C-9,
occurs in the respective dextrorotatory (rotate plane polarized
light in a clockwise [⫹] direction) diastereomers, QD, hydroquinidine (HQD), and cinchonine (CN). The 8,9-threo diastereomers 9-epiquinine (EQN) and 9-epiquinidine (EQD) are 8S,
9S, and 8R, 9R, respectively.
Against Plasmodium falciparum, the CA diastereomer pairs
have a well-established in vitro potency order. The dextrorotatory
isomers QD, HQD, and CN have greater antimalarial potencies
than their levorotatory counterparts, QN, HQN, and CD (22, 37,
68). EQN (weakly dextrorotatory) and EQD (dextrorotatory) are
comparatively ineffective; a previous study noted lower efficacies
of approximately 100-fold compared to QN and QD (37). Observations of stereospecificity extend to in vivo studies on QN and
QD efficacy against P. falciparum, where the latter is the more
potent clinically (62, 69).
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The mechanism of action of the quinoline aminoalcohol QN
and the blood schizontocidal 4-aminoquinolines, including CQ,
is believed to depend upon their weakly basic properties that promote accumulation to high levels in the acidic digestive vacuole
(DV) of intraerythrocytic trophozoite-stage parasites. Once inside
the DV, they presumably bind free heme (monomeric or dimeric
Fe[III] protoporphyrin IX) (1, 18), a toxic intermediate produced
from parasite proteolysis of host hemoglobin (21, 41, 65). Heme
binding is thought to inhibit the formation of the more inert
microcrystalline compound hemozoin, creating a poisonous
buildup of lethal drug-heme complexes (48). Resistance to CQ,
and possibly reduced QN potency, is linked to enhanced efflux of
drug from resistant parasites (40).
Mutations in the pfcrt (Plasmodium falciparum chloroquine
resistance transporter) gene are the primary cause of CQ resistance and also greatly affect QN susceptibility (20, 26). PfCRT, a
protein containing 424 amino acids and 10 predicted transmembrane domains (Fig. 2), is thought to be a channel or transporter of
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mulation (11). Our earlier studies demonstrated that in addition
to producing CQ resistance in P. falciparum, a novel PfCRT K76I
mutation resulted in a dramatic increase in QN susceptibility,
reversing the normally observed potency order of QD ⬎ QN (14,
26). By taking advantage of the unique antagonistic properties of
verapamil against QN in the K76I mutant clone, we used Schild
analysis (2) to show that PfCRT probably binds QN (16).
The steric and electronic features of the CA that contribute to
the potency of the erythro conformations are believed to impart an
enhanced ability to form intramolecular hydrogen bonds with a
plasmodial receptor(s) (18, 35, 36). Although the presence of such
a target molecule serving as a stereoselective receptor appears evident in the action of the CA, the nature of this receptor has yet to
be determined. Here, we have tested a panel of eight isogenic parasite clones with a series of PfCRT polymorphisms against four
pairs of CA diastereomers. Our data show that stereospecific drugPfCRT interactions are important determinants of CA potency
against P. falciparum.
MATERIALS AND METHODS

FIG 1 Chemical structures of CA and MQ stereoisomers used in this study.

the drug-metabolite transporter (DMT) superfamily (43). Although the endogenous function of PfCRT remains enigmatic, its
localization within the DV membrane in trophozoite-stage parasites agrees with a role in drug resistance (14). Evidence suggests
that mutated PfCRT, in particular a K76T mutation, confers CQ
resistance by allowing enhanced efflux of CQ from the DV,
thereby reducing the concentration of drug available to bind target heme (8, 9, 57). However, the cytotoxic properties of CQ may
involve additional PfCRT-related mechanisms beyond DV accu-
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Materials. QN, QD, HQN, HQD, CD, CN, and amantadine (AMT) were
purchased from Sigma-Aldrich Chemical Co. The erythro CA were used
without further purification despite containing up to 5 to 15% of isomers
of the same rotation. EQN and EQD were kindly provided by G. Reinecke
of Buchler Gmbh, Braunschweig, Germany. Racemic mefloquine (MQ)
was obtained from the Walter Reed Army Institute for Research (Silver
Springs, MD). The (⫺)- and (⫹)-12,11 erythro MQ enantiomers were
synthesized by D. Sturchler at Hoffmann-La Roche, Basel, Switzerland,
and kindly provided by W. Peters (London School of Hygiene and Tropical Medicine). Purity information was not available on the 9-epimers and
MQ enantiomers, but 50% inhibitory concentrations (IC50s) against control P. falciparum lines for these compounds were in agreement with literature values (37, 38). SYBR green I was purchased from Cambrex Corp.
Drug stocks were prepared to 10 mM in 70% ethanol and maintained at
⫺30°C.
Parasite cultivation and drug selection. Parasites were cultured using
AB⫹ or O⫹ red blood cells in complete medium consisting of RPMI 1640
supplemented with 0.5% Albumax I (Invitrogen), 29.8 mM sodium bicarbonate, 25 mM HEPES, 0.37 mM hypoxanthine, and 0.01 mg/ml gentamicin and maintained at 37°C under an atmosphere of 90% nitrogen,
5% carbon dioxide, and 5% oxygen. CQ-resistant control parasites Dd2
and 7G8 and the CQ-sensitive HON (parental line of HB3) and 106/1K76
strains were kindly provided by Thomas E. Wellems, National Institute of
Allergy and Infectious Diseases (Rockville, MD). Drug-resistant lines of P.
falciparum were selected on the clonal 106/1K76 line by single-step drug
selection (52) as described previously (14, 16). The PfCRT mutants 106/
176N, 106/176T, and 106/176I were selected from 106/1K76 by using 100 nM
CQ. Double PfCRT mutants were generated by an additional round of
single-step selection on cloned 106/176I with either 100 nM QN or 80 M
AMT (Table 1). A selection experiment consisted of four individual 150cm2 culture flasks containing the desired parent parasite line. Each flask
contained 50 ml of mixed-stage culture with a 5% hematocrit and ⬃5%
parasitemia, representing ⬃109 parasites/flask. Upon reaching 5% parasitemia, drug was added at the specified concentration, which was sufficient to rapidly kill all parasites except for any preexisting, drug-resistant
mutants (52). Cultures were maintained for 60 days under drug pressure
and monitored by Giemsa smears for the presence living parasites. Successful selections, considered the presence of emergent parasites, occurred
on average once every 10 flasks (14); thus, most four-flask experiments
did not yield mutant lines. All emergent lines were cloned by limiting
dilution (27) prior to DNA sequencing and drug susceptibility testing.
Sequence analysis of pfcrt and pfmdr1 genes. Four randomly chosen
clonal lines were used for pfcrt sequencing from a successful selection
experiment. All open reading frame sequences of pfcrt were amplified
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FIG 2 Topographic representation of PfCRT. Arrows and clear circles indicate polymorphic amino acids described in this study. PfCRT contains 424 amino
acids and has 10 predicted transmembrane domains (43).

from P. falciparum genomic DNA (63). From clonal lines chosen for further study, the entire open reading frame of pfmdr1, or known polymorphic regions of pfmdr1, were amplified from genomic DNA using primers
described previously (44, 51). PCR products were directly sequenced using an ABI 3730xl DNA analyzer (Applied Biosystems).
Determination of pfmdr1 copy number by real-time PCR. The copy
number of pfmdr1 was estimated in mutant lines of P. falciparum by TaqMan real-time PCR using an ABI 7900HT Fast real-time PCR system as
described previously (54). Assays were conducted in four independent
replicates and normalized to HB3 genomic DNA, which was included in
every run. The copy number for 7G8 was from Sa et al. (54a).
Drug response assays. The in vitro susceptibility of P. falciparum to
the CA was measured in a 72-h, 96-well microplate fluorescence assay
using SYBR green I detection as described previously (6, 61). Parasites
were introduced into the drug assay at ⬃48-h intervals until at least three

independent replicates were performed. Mean half-maximal inhibitory
concentrations (IC50s) were derived by plotting the percent growth inhibition against the log drug concentration and fitting the response data to
a variable slope, sigmoidal curve-fit function for normalized data by using
Prism 5.0d for Macintosh (GraphPad Software). IC50s represent means ⫾
standard errors of the means (SEM) from 3 to 8 independent tests. Relevant IC50s between respective mutant and parental lines were tested for
statistically significant differences by an F test to determine whether two
dose-response data sets were best described by single or independent
curve fits (P ⬍ 0.05).
Correlation of PfCRT position 76 amino acid hydropathy with (ⴚ)/
(ⴙ) CA IC50 ratios. Hydropathy values at pH 5.0 for the mutable position
76 residues N, T, and I were those described in reference 39. Because the
hydropathy value for N was assigned a 0 (39), an arbitrary value of 4 was
added to each coefficient to accommodate log transformation. Log hy-

TABLE 1 PfCRT haplotypes, geographic origins, and CQ susceptibility profiles of P. falciparum lines used in this studya
PfMDR1e

Variable PfCRT amino acids
Parasite

Origin

HON
7G8
Dd2
106/1K76
106/176N
106/176T
106/176I
106/172R-76I
106/176I-352R
106/176I-352K
106/176I-369F

Honduras
Brazil
Thailand
Sudan
Lab
Lab
Lab
Lab
Lab
Lab
Lab

Selectionb

CQc

CQ
CQ
CQ
CQ-QN
CQ-QN
CQ-QN
CQ-AMT

S
R
R
S
R
R
R
S
S
S
I

Dayd

72

74

75

76

220

271

326

352

356

369

371

Allele

CN

42
33
28
37
32
34
42

C
S
C
C
C
C
C
R
C
C
C

M
M
I
I
I
I
I
I
I
I
I

N
N
E
E
E
E
E
E
E
E
E

K
T
T
K
N
T
I
I
I
I
I

A
S
S
S
S
S
S
S
S
S
S

Q
Q
E
E
E
E
E
E
E
E
E

N
D
S
S
S
S
S
S
S
S
S

Q
Q
Q
Q
Q
Q
Q
Q
R
K
Q

I
L
T
I
I
I
I
I
I
I
I

V
V
V
V
V
V
V
V
V
V
F

R
R
I
I
I
I
I
I
I
I
I

NFSDD
NFCDY
YYSND
YYSND
YYSND
YYSND
YYSND
YYSND
YYSND
YYSND
YYSND

1
1
3
2
2
2
1
1
1
2
—f

a
Lines were derived from 106/1K76 by single-step drug selection as described in Materials and Methods. Shaded boxes indicate mutant amino acids selected in this work relative to
106/1K76.
b
Drug(s) used to select the indicated mutant line by single-step selection. All double mutant lines were generated from the CQ-selected single mutant line 106/176I. Listed after CQ
is the drug used in the second round of single-step selection.
c
R, CQ resistant; S, CQ sensitive; I, CQ intermediate.
d
Day at which mutant parasites were first observed in culture.
e
Amino acid residues at known polymorphic PfMDR1 positions 86, 184, 1034, 1042, and 1246. CN, pfmdr1 copy number, as determined by real-time PCR.
f
—, no data.
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7G8c
Dd2c

18 ⫾ 0.6
116 ⫾ 9.8
57 ⫾ 3.3
105 ⫾ 8.1
75 ⫾ 16
234 ⫾ 11
93 ⫾ 4.0
7,344 ⫾ 567
10,930 ⫾ 984

106/1K76

99 ⫾ 0.1*
91 ⫾ 10*
25 ⫾ 2.5*
147 ⫾ 13*
56 ⫾ 3.4*
204 ⫾ 15
54 ⫾ 6.0*
13,380 ⫾ 1,500*
7,656 ⫾ 82*

106/176Nc

180 ⫾ 11*
152 ⫾ 17*
59 ⫾ 4.8
175 ⫾ 9.7*
110 ⫾ 5.0*
348 ⫾ 15*
93 ⫾ 3.6
19,936 ⫾ 1,358*
16,241 ⫾ 1,056*

106/176Tc

259 ⫾ 8.1*
19 ⫾ 1.2*
38 ⫾ 2.8*
20 ⫾ 2.2*
74 ⫾ 5.4
87 ⫾ 3.1*
61 ⫾ 2.7*
4,843 ⫾ 229*
8,730 ⫾ 452*

106/176Ic

53 ⫾ 3.2†
28.1 ⫾ 3.4†
30.5 ⫾ 1.3†
13.1 ⫾ 1.5†
24.7 ⫾ 1.0†
38.9 ⫾ 3.0†
48.4 ⫾ 1.5†
233 ⫾ 38†
892 ⫾ 93†

106/176I-369F

15 ⫾ 0.9†
68 ⫾ 2.9†
42 ⫾ 2.2
102 ⫾ 5.4†
50 ⫾ 2.3†
231 ⫾ 17†
62 ⫾ 2.9
3,306 ⫾ 211†
3,630 ⫾ 213†

106/176I-352K

24 ⫾ 0.4†
116 ⫾ 17†
28 ⫾ 1.2†
112 ⫾ 7.0†
43 ⫾ 2.3†
222 ⫾ 24†
73 ⫾ 11†
2,149 ⫾ 137†
4,098 ⫾ 218†

106/176I-352R

18 ⫾ 0.3†
69 ⫾ 11†
25 ⫾ 0.83†
87 ⫾ 4.3†
36 ⫾ 1.2†
201 ⫾ 14†
58 ⫾ 5.9
2,563 ⫾ 90†
4,855 ⫾ 295†

106/172R-76I

IC50 (nM) in parasite lineb

HON

174 ⫾ 5.4
145 ⫾ 18
75 ⫾ 4.9
215 ⫾ 10
121 ⫾ 6.1
378 ⫾ 42
218 ⫾ 13
16,340 ⫾ 1,548
15,440 ⫾ 1,092

TABLE 2 Activities of the CA against control and PfCRT mutant lines of P. falciparum in culturea

Drug

118 ⫾ 3.1
87 ⫾ 6.1
42 ⫾ 3.3
119 ⫾ 4.9
36 ⫾ 3.6
337 ⫾ 12
76 ⫾ 6.2
22,440 ⫾ 1,003§
31,720 ⫾ 2,083§
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15 ⫾ 0.2
101 ⫾ 8.8
31 ⫾ 3.3
92 ⫾ 8.2
32 ⫾ 3.2
287 ⫾ 40
37 ⫾ 3.3
9,458 ⫾ 971
13,111 ⫾ 1,584

Selection of PfCRT mutant lines of P. falciparum. PfCRT mutant parasites were selected from the CQ-sensitive parental line
Sudan 106/1 (designated 106/176K here) (4, 14, 16). This parasite
strain is appropriate for single-step drug selection studies, as
the pfcrt allele contains all mutations necessary for CQ resistance
other than the single critical point mutation that results in the
K76T polymorphism (14, 16, 26) (Table 1). The selection of all
mutants reported here, except 106/176I-369F, has been described in
detail elsewhere (14, 16). Western blotting demonstrated similar
expression levels of PfCRT from these parasite lines (16), and
nucleotide sequencing demonstrated that no mutations were selected in pfmdr1 (Table 1). In the absence of drug pressure, all
measured drug phenotypes have remained stable in long-term
cultures (⬎6 months). In addition to the clone presented in this
report, the 106/176I line has been selected on multiple independent occasions, each time producing identical phenotypes to all
drugs tested, providing strong evidence for the role of the PfCRT
mutation in the CA responses (14, 16, 26). Finally, transfection of
the K76I PfCRT allele into the GC03 line of P. falciparum resulted
in similar drug responses to 106/176I, despite the differing genetic
background of the recipient parasite line and greatly reduced expression levels of transgenic PfCRT (60).
AMT shows a strong inverse potency relationship with CQ
against P. falciparum and has been previously used for the selection of novel PfCRT mutations in CQ-resistant parasites (34). Our
AMT-resistant mutant was generated by single-step selection with
CQ on 106/1K76 to generate 106/176I, followed by an additional
round of single-step selection with 80 M AMT to generate an
AMT-resistant parasite. Parasites were first observed in culture
after 42 days of continuous AMT pressure, and emergent parasites
were found to possess a novel V369F PfCRT mutation (Table 1)
predicted to occur in the DV loop between transmembrane domains 9 and 10 (43) (Fig. 2). Once cloned, drug susceptibility
assays showed that 106/176I-369F had become ⬃90-fold more resistant to AMT, with an IC50 of 387 ⫾ 20 M, compared to 4.4 ⫾ 0.3
M for the 106/176I parental line. The double mutant also became
nearly 5-fold more susceptible to CQ after acquiring the V369F
mutation (Table 2).
Parasite susceptibility to the CA is associated with PfCRT
polymorphisms. In earlier studies, we demonstrated that a PfCRT
K76I mutation greatly increased susceptibility to QN but not to
QD, resulting in a reversal of the normal isomer potency order,
where QD is 2- to 4-fold more potent than QN (14). To further
characterize the relationship between PfCRT and the three-dimensional structure of CA, we measured the in vitro potency of
four diastereomer alkaloid pairs against a set of pfcrt mutant parasite clones derived from the 106/1K76 strain (Table 1). The resulting IC50s showed that, among the pharmacologically active erythro
alkaloids, the dextrorotatory (⫹) QD, HQD, and CN (8R, 9S)
were 1.7- to 7.7-fold more potent than the levorotatory (⫺) QN,
HQN, and CD (8S, 9R) against all control parasite lines and

CQ
QN
QD
HQN
HQD
CD
CN
EQN
EQD

RESULTS

a
Values are mean ⫾ SEM IC50s (in nM) determined from 3 to 8 independent 72-h growth inhibition assays.
b
pfcrt mutant lines were derived from 106/1K76 by single-step drug selection (14, 16). Superscripts indicate mutant positions in PfCRT. F, phenylalanine; K, lysine; I, isoleucine; N, asparagine; R, arginine; T, threonine. 7G8 and Dd2 are
CQ-resistant control lines. HON is a CQ-sensitive control line. *, significantly different average IC50 from 106/1K76 parent line (F test; P ⬍ 0.05); †, significantly different average IC50 from 106/176I parent line (F test; P ⬍ 0.05); §,
significantly different average IC50 compared to HON or Dd2 lines (F test; P ⬍ 0.05).
c
CQ-resistant line.

dropathy was plotted against the log (⫺)/(⫹) IC50 ratios for all alkaloid
pairs (QN/QD, HQN/HQD, CD/CN, and EQN/EQD). Using the same
drug susceptibility data described above, log IC50 ratios (n of 3 to 6) were
calculated from respective CA IC50 pair data from within individual assay
plates. Log ratio data were averaged and plotted, ⫾ SEM, for each CA
diastereomer pair. Linear regression was performed using the GraphPad
Prism 5.0 software. The slope value of the linear fit was tested for a statistical difference from zero (P ⬍ 0.05).
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clones, with the exception of 106/176I and 106/176I-369F (Table 2).
Among the CQR pfcrt mutants, trends emerged that (⫹)/(⫺) IC50
ratios increased (76N and 76T) or decreased (76I) relative to the
original 106/1K76 parent line.
These increased potency differences were primarily due to the
selective change in susceptibility to either the (⫺) or (⫹) diastereomer, depending on PfCRT mutation. Relative to 106/1K76 parent, in the 106/176T line, which carries the K76T mutation ubiquitously observed in CQ-resistant field isolates, a decreased
susceptibility to the (⫺)-isomers QN, HQN, and CD and to the
weakly (⫹) EQN was observed. Little effect was seen on response
to the (⫹)-isomers, except for a slight loss in sensitivity to HQD.
In contrast, the 106/176N line primarily showed increased susceptibility to the (⫹)-isomers QD, HQD, CN, and (⫹) EQD, with
some loss of sensitivity to the (⫺)-isomer HQN and the weakly
(⫹) EQN. Most notably, against 106/176I we observed a selective
increase in potency of the (⫺)-isomers up to 7-fold compared to
the 106/1K76 line. Only a slight increase in potency was observed
for the (⫹)-isomers QD and CN, and no change was observed
with HQD. In sum, the selective increase in susceptibility to the
(⫺)-isomers by 106/176I resulted in a reversal of the normally
reported potency order of QN ⬎ QD and HQN ⬎ HQD. The
effect on the CD/CN pair was less dramatic. Although relative CN
potency diminished 2.5 times to 1.4 times more than CD, the
potency order remained in keeping with the parent line (Table 2).
Because of the great sensitivity of 106/176I to QN (IC50, 19 nM),
we previously used single-step QN pressure to select three additional PfCRT mutants from this line: 106/172R-76I, 106/176I-352K,
and 106/176I-352R (Table 1) (16). These double mutants all acquired a positively charged lysine or arginine in substitution for a
neutral residue, while retaining the 76I residue. As expected, all
three lines showed elevated QN IC50s compared to 106/176I, yet
they also became sensitive to CQ (16). Accompanying the increase
in the QN IC50, the double mutants had parallel increases in IC50s
for the other (⫺)-isomers, CD and HQN, ranging from 2.3- to
5.6-fold. Comparatively little effect was seen on IC50s for the (⫹)isomers QD, CN, and HQD following selection of the position 72
or 352 mutations. These results show that the secondary mutations at PfCRT position 72 or 352 abrogated the stereoselective
effect of the K76I mutation on the CA. Among these double mutants, no clear trends were observed in drug susceptibilities, other
than a slightly elevated QN response in 106/176I-352R (Table 2).
Relative to the 106/176I parent line, AMT-selected 106/176I-369F
was more susceptible to all the erythro CA, with the exception of a
slight increase in the QN IC50 (Table 2). While no clear trends
were observed among isomers, potency differences between diastereomer pairs were largely abrogated by the V369F mutation.
Three reference control strains, Dd2, 7G8, and HON, were
chosen for this study based on their diverse PfCRT haplotypes and
CQ susceptibility profiles (26) (Table 1). Predictably, the dextrorotatory isomers QD, HQD, and CN had greater in vitro potencies
than the levorotatory QN, HQN, and CD against these lines (Table 2). The CQ-sensitive HON strain showed increased sensitivity
to all CA tested, other than QN, compared to the CQ-resistant
controls 7G8 and Dd2. The Dd2 and 106/176T lines both carry the
K76T mutation ubiquitously found in CQ-resistant isolates, differing only by a threonine-to-isoleucine substitution at PfCRT
position 356 (15). Not surprisingly, the responses for the two lines
were similar for all CA. The minor inherent differences in IC50s
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may be attributed to both the position 356 PfCRT amino acid
change (Table 1) and also genetic background differences.
Compared to the erythro alkaloids, the threo alkaloids EQN and
EQD were previously shown to be about 10 to 100 times less potent against CQ-resistant and CQ-sensitive strains, respectively, of
P. falciparum (37). With one exception, 106/176I-369F, we observed
similarly weak activity, although there were clearly response
changes to EQN and EQD associated with PfCRT mutations. The
South American line 7G8, which contains a unique CQ-resistant
PfCRT haplotype compared to Dd2 and HON, was significantly
(P ⬍ 0.05) more resistant to both 9-epimers (Table 2). The only
apparent trends were observed among the double PfCRT mutants.
The double mutants were all significantly more sensitive to EQN
and EQD than either the single mutant 106/1K76 or 106/176I parent
lines. EQN was slightly more potent than EQD against the double
mutants, while the potency order varied with no obvious trend
revealed among the other lines. Surprisingly, 106/176I-369F became
⬃9- to 16-fold more susceptible to the normally weakly active
9-epimers relative to 106/176I, with EQN displaying nearly 4-fold
greater potency than EQD. Based on the weak activity of the
9-epimers against the other parasite lines, it was unlikely that the
large increase in potency against 106/176I-369F was due to impurities consisting of the active erythro alkaloids.
Among the CQ-resistant mutants, PfCRT hydropathy is correlated with CA (ⴚ)/(ⴙ)-isomer IC50 ratios. Earlier, we demonstrated that among CQ-resistant clones derived from 106/1K76, a
positive correlation exists between the CQ IC50 and hydrophobicity of the PfCRT position 76 residue (16). Therefore, we examined
the hydropathy of these same residue side chains in relation to the
differential effects of the CA isomers. Hydropathy values of amino
acid side chains within a standardized synthetic polypeptide structure were determined at pH 5.0 by Kovacs et al. (39). This pH
value is within the measured pH range for the P. falciparum DV
lumen (5, 28), where the PfCRT position 76 amino acid is predicted to face (Fig. 2) (43). Log IC50 ratios for all four CA pairs
were plotted against log-transformed hydropathy values for N, T,
and I residues corresponding to the CQ-selected mutants (Fig. 3).
The log (⫺)/(⫹)-isomer ratios clearly decreased as the PfCRT
position 76 residue becomes more hydrophobic (P ⬍ 0.0001) for
all CA pairs. We also conducted a t test between the mean log IC50
ratios of the N and T residue, as the I value could leverage the
regression due to its more extreme position on the plot. All N
versus T mean log IC50 ratios were significantly different (t test, P
⬍ 0.05), except for the CD/CN pair, which differ from the other
CA in their lack of the quinoline methoxy group. Inclusion of data
from the geographically disparate 7G8 and Dd2 lines reduced the
significant difference between 76N and 76T CA ratios (t test, P ⬎
0.05), possibly due to influences of the different pfcrt alleles and in
other genetic loci on drug susceptibility (24).
CA phenotypes are independent of polymorphisms or gene
copy number changes in pfmdr1. The entire pfmdr1 open reading
frame from the 106/1 parasite set was sequenced, except for 106/
176I-372R and 106/172R-76I, where sequencing was limited to regions
flanking and including the key polymorphic codons 86, 184, 1034,
1042, and 1246. No changes were detected in the sequence of any
of the mutant parasites relative to the parental 106/1K76. All lines
contained an identical pfmdr1 allele (YYSND), with one mutation,
N86Y, relative the “wild-type” allele (NYSND) (Table 1).
The copy number of the pfmdr1 gene was assessed in seven
mutant lines by using quantitative real-time PCR (Table 1). The
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DISCUSSION

FIG 3 (⫺)/(⫹) CA IC50 ratios correlate with pH 5 hydropathy coefficients of
PfCRT position 76 residues from CQ-resistant mutants of 106/1K76. The log
(⫺)/(⫹) IC50 ratios of the four CA pairs were plotted as a function of the
log(hydropathy coefficient ⫹ 4), as described in reference 39. Error bars
represent SEM of the average within-plate IC50 ratios as described in Materials and Methods. The slopes of the regression lines were as follows: for
QN/QD, y ⫽ ⫺1.13x ⫹ 1.29, and R2 ⫽ 0.94; for HQN/HQD, y ⫽ ⫺1.29x ⫹
1.22 and R2 ⫽ 0.93; for CD/CN, y ⫽ ⫺0.60x ⫹ 1.02 and R2 ⫽ 0.89; for
EQN/EQD, y ⫽ ⫺0.55x ⫹ 0.53 and R2 ⫽ 0.90. All slopes values are significantly different from zero (P ⬍ 0.0001). Average log(⫺)/(⫹) IC50 ratios
were also compared for N versus T by t test, to control for a disproportionate effect on the regression by the more extreme hydropathy coefficient of
I (see Results). Letter abbreviations for the corresponding PfCRT position
76 amino acids are shown adjacent to the data points on the graph.

parental 106/1K76 line was determined to have two copies of
pfmdr1. Following drug selection, 106/176I was found to have one
copy, while 106/176N and 106/176T remained with two copies.
Double mutants, selected from 106/176I, were single copy, except
for 106/176I-352K, which had reverted to the original two copies of
pfmdr1. No apparent trend was observable between CA responses
and pfmdr1 copy number.
Potency order of (ⴙ)- and (ⴚ)-MQ isomers unchanged by a
PfCRT K76I mutation but altered by a secondary V369F mutation. It has been shown that the enantiomers of MQ, a synthetic
quinoline aminoalcohol analog of QN and QD (Fig. 1), also possess differential activities against P. falciparum. The (⫹)-isomer of
MQ, shown to be the stereo-equivalent of QD in terms of absolute
conformation, reportedly has 1.7 to 1.8 times greater activity than
(⫺)-MQ, the QN equivalent (36, 38). We tested 106/1, 106/176I,
and 106/176I-369F (Table 3) in drug assays to determine if the unusual effects of these PfCRT mutations on the CA was extended to
the structurally similar MQ isomers. We observed a potency increase in both MQ enantiomers associated with the PfCRT K76I
mutation, consistent with the increase in potency of racemic MQ
that we reported earlier against this clone (14). We found that
(⫹)-MQ was 1.6 times more potent than (⫺)-MQ against the
106/1K76 parent line and 2.6 times more potent against 106/176I.
Thus, despite the presence of a PfCRT mutation that imparts stereospecific changes to CA activity, the difference in MQ isomer
potency order was unchanged from the 106/1K76 parent line, as
well as from that of parasite isolate data reported from earlier
studies (38). In contrast, isomer potency differences were lost
against 106/176I-369F, consistent with observations of this line
against the erythro CA. It is possible that the loss of a pfmdr1 copy
(Table 1) contributes to the increase in MQ susceptibility by 106/
176I compared to the parent line. MQ responses are closely linked
to pfmdr1 copy number changes (17, 58).
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In P. falciparum, polymorphisms in the PfCRT protein confer CQ
resistance and profoundly influence susceptibility to QN and QD
(14, 26). The pfmdr1 gene, encoding a P-glycoprotein-like ABC
transporter, can also modulate CQ and QN responses through
mutations and changes in gene copy number (53, 58, 59). Recently, polymorphisms in a P. falciparum-encoded Na⫹/H⫹ exchanger, PfNHE-1, were linked to in vitro QN susceptibility in
laboratory-adapted and clinical isolates in some studies, but not in
others (3, 10, 24, 31, 50). Neither mutations in pfnhe-1 or pfmdr1
nor gene copy number in the latter are known to influence stereospecific responses to CA (7, 24, 49, 59). Our findings support
PfCRT as a major parasite-encoded determinant of CA susceptibility and stereospecificity, although additional genes, gene interactions, and other genomic changes likely contribute parasite responses to the CA (24, 33).
Although no effects on CA responses were discernible, a
pfmdr1 deamplification was seen in some 106/1 mutants (Table 1),
resulting from the reduction from two gene copies to one in the
106/176I line. Many studies have shown that pfmdr1 expression
levels are associated with P. falciparum susceptibility to QN, although the relationship is dependent on the genetic background
of the parasite (55). Indeed, QN responses were not associated
with pfmdr1 copy number in other recent in vitro and in vivo
studies (12, 13), nor is there evidence of linkage of QN responses
with copy number among progeny in the HB3 ⫻ Dd2 genetic
cross (24; M. T. Ferdig, unpublished data). While the increased
QN susceptibility of 106/176I may be in part attributed to the loss
of a pfmdr1 gene copy, transfection studies have shown that the
K76I pfcrt allele also confers a similar phenotype (60).
The stereoselective pharmacological properties of QN and QD
have been documented against several classes of bacterial and
mammalian transporters (29, 30, 32, 46, 47), underscoring the
importance of drug-receptor binding in their mechanisms of action. Against P. falciparum, the CA (⫹)-isomers are normally
more potent than the (–)-isomers, and evidence points to the
necessity of drug-heme binding in their mechanism of action (1,
21, 45). Compared to QN, QD may possess a greater binding
affinity for heme monomer under both aqueous and aprotic conditions and more potently inhibit ␤-hematin (the synthetic equivalent of hemozoin) formation (1, 18), providing a plausible explanation for the greater potency of the (⫹)-isomers. However,
analysis of additional CA and other QN analogs failed to establish
a clear correlation between drug-heme binding affinity, inhibition
of ␤-hematin formation and in vitro potency (1). Observed stereospecific changes in the CA response could also be a conseTABLE 3 Effects of PfCRT K76I and V369F mutations on susceptibility
to (⫹)- and (⫺)-MQ stereoisomers
IC50 (nM) in parasite linea
Drug

106/1K76

106/176I

106/176I-369F

(⫹)-MQ
(⫺)-MQ
[(⫹)(⫺)]b MQ
MQ (racemic)

13.5 ⫾ 0.7
21.2 ⫾ 1.0
18.3 ⫾ 1.0
14.4 ⫾ 1.3

2.3 ⫾ 0.3*
5.9 ⫾ 0.9*
5.1 ⫾ 0.7*
3.1 ⫾ 0.4*

3.3 ⫾ 0.3†
3.4 ⫾ 0.3†
3.4 ⫾ 0.3†
3.1 ⫾ 0.3

a
Values are means ⫾ SEM derived from 3 independent assays. *, significantly different
average IC50 from 106/1K76 parent line (F test; P ⬍ 0.05); †, significantly different
average IC50 from 106/176I parent line (F test; P ⬍ 0.05).
b
A 50/50 mixture of the (⫹)- and (⫺)-isomers.
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quence of altered drug-heme binding in the DV due to changes in
the chemical environment imparted by mutant PfCRT. Based on
the differences in the quinoline N pKa of QN and QD, it was
predicted that subtle changes in DV pH, such as a putative increased acidity related to PfCRT mutations, can significantly increase accumulation of the (⫹) diastereomer QD (41). However,
this theory is inconsistent with the measured (and albeit controversial) decrease in DV pH in 106/176I and the selective increase in
sensitivity to QN and the other (–) diastereomers (6, 14).
The hydropathy of certain mutable PfCRT residues shows
quantitative relationships with susceptibility to CQ and desethylamodiaquine (16, 64). Among the CQ-resistant 106/1 mutants,
the patterns of CA susceptibility suggest complex interactions between the physicochemical features of the drug and the threedimensional and chemical environment of the PfCRT pore. This
was further investigated by plotting (–)/(⫹) CA IC50 ratios in
relation to PfCRT amino acid 76 hydropathy. A clear log-log correlation was found between the IC50 ratios for all four CA pairs
and residue 76 hydrophobicity (Fig. 3), indicating that the striking
effect on diastereomer sensitivity by the K76I mutation (14, 16) is
not unique. The loss-of-charge mutations may increase the potential for hydrophobic interactions with some quinolines, suggesting greater drug access to the PfCRT channel in CQ-resistant isoforms. In the case of K76, since the diastereomer pairs are
practically mirror images, an attractive explanation of stereospecific drug susceptibility is that the positively charged lysine sees
first the hydrophobic side of QN (perhaps involving the aromatic
quinoline ring and methoxy group); no interaction occurs and a
proportion of drug molecules escape the DV. For QD, K76 sees the
hydrophilic positively charged quinuclidine ring first and QD is
repelled from entering the transporter, and it is thus retained in
the DV to a greater extent. Along with drug molecule bulk that
also determines the stringency with which a binding site distinguishes between (–) and (⫹) isomers, this could account for the
general superiority of dextrorotatory CA against CQ-sensitive
strains and the K76T and K76N mutants. CA susceptibility may
also result from PfCRT binding (16) and subsequent inhibition of
the endogenous function of the transporter itself (56). The different IC50s that accompany the PfCRT amino acid changes could
therefore reflect relative CA-receptor binding affinities, which in
turn may dictate DV drug accumulation levels and heme-binding
equilibrium.
In contrast to the wide range in CA susceptibility among the
CQ-resistant parasite lines, the control line, HON, and the CQsensitive pfcrt mutants showed very similar responses to the
erythro CA. The positive charge of a key lysine or arginine residue
in either transmembrane domain 1 or 9 of these lines (16) may
reduce binding with CA due to electrostatic repulsion, and in
keeping with this action, reduce the interactions responsible for
stereospecificity. In the acidic DV (pH, ⬃5.2), the CA will be
mostly in the monoprotic form due to protonation of the aliphatic
nitrogen (66). This similarity in IC50s exists alongside three polymorphisms in the HON PfMDR1 (Y86N, Y184F, and N1042D)
(49) relative to 106/1K76, emphasizing the dominant role of the
wild-type PfCRT transporter in CA susceptibility.
Our results demonstrate that a PfCRT position 76I residue in
combination with a second-site mutation leads to a significant
increase in the activity of the threo 9-epimers against P. falciparum
(Table 2). Results from crystallographic studies suggested that,
due to their rotational conformation, the 9-epimers are unable to
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form the same intramolecular hydrogen bond with the heme propionate as do the active erythro CA, resulting in weak potency (18).
These data are consistent with observations that neither EQD nor
EQN, in contrast to the erythro CA, inhibit ␤-hematin formation
in vitro (1, 21, 66). Additionally, the reduced lipid-aqueous
distribution coefficients of the 9-epimers due to the higher pKa
values of the quinuclidine aliphatic nitrogen compared to that
of the erythro CA are predicted to reduce solubility in the parasite membrane by a factor of 12.6 (66). Further studies are
needed to determine if the K76I PfCRT double mutants retain
more of the threo CA in the DV than do the other mutant lines.
An earlier study identified the vacuolar loop between putative
transmembrane domains 9 and 10 as part of the PfCRT-binding
site for AzBCQ, a CQ analog and photoaffinity label (42). Binding
of the affinity label was competitively inhibited by QN, suggesting
overlap in their respective binding sites. These results are consistent with our observations here, as the PfCRT V369F change occurs within this same loop region (Fig. 2) and is associated with
increased susceptibility to the CA and CQ (Table 2). We propose
that the bulky, rigid, and hydrophobic 369F side chain sterically
hinders the ability of quinolines to escape the DV through the
PfCRT pore, or it may serve as an alternative hydrophobic CA
binding site to 76I where the CA drugs are less sterically constrained, in this case in the DV lumen. Steric constraint by 369F on
the exit of CQ from the DV is also plausible, as hydrophobic interactions are unlikely since CQ is doubly protonated at DV and
cytoplasmic pH values (25).
The synthetic quinoline aminoalcohol derivative MQ retains
equivalent chiral centers (C-12 and C-11) to C-8 and C-9 of the
CA (36) (Fig. 1). Superposition of (⫹)-MQ with QD showed identical positioning of the quinoline rings, amine, and hydroxyl
groups for the two compounds. Favorable orientation of the aliphatic amine and hydroxyl groups for hydrogen bonding with a
malaria receptor has been proposed to explain the potency advantage of (⫹)-MQ or QD over the respective enantiomer or diastereomer (38). Unlike the pronounced effects on the CA, drug assays with (⫹)- and (–)-enantiomers of MQ against 106/176I and
106/176I-369F showed little effect on MQ potency order (Table 3). It
is of note that, in contrast to threo CA, the racemate of 12, 11 threo
MQ is as potent as the racemate of 12, 11 erythro mefloquine
against Plasmodium berghei and P. falciparum in vitro (38, 67).
This difference reflects the increased ease of rotation around the
link between the asymmetric carbon atoms due to the lower bulk
of the piperidine ring as opposed to that of quinuclidine (36, 67).
The bulkier quinuclidine side chain of the CA may contribute to a
loss of flexibility, imparting a structural constraint that may confer the greater stereospecificity of the CA than the other quinolines
(19). Alternatively, as MQ is a substrate for PfMDR1 (23), stereospecificity may be determined by interactions with this protein
or heme, and not by PfCRT. Transfection studies with the K76I
PfCRT allele, and pfmdr1 knockdown experiments clearly support
a role for both transporters in the increased sensitivity to MQ by
106/176I (58, 60).
Taken together, our data suggest that the well-established potency order of QD ⬎ QN is dictated by the PfCRT haplotypes
found in CQ-sensitive (K76) and -resistant (K76T) field and lab
isolates. In CQ-sensitive parasites, electrostatic repulsion between
critical lysine/arginine residues (position 72, 76, or 352) and CA
may prevent these drugs from participating in stereospecifically
determined hydrophobic interactions but apparently allows more
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repulsion of (⫹) diastereomers. Mutant parasite lines with alternative 76N/T/I side chains reveal distinct stereospecific interactions with CA, indicating greater access of the drug to stereodetermining residues in the CQ-resistant forms of the PfCRT
channel. These highly specific interactions implicate PfCRT as a
receptor or binding site for the CA. Binding may dictate drug
potency by determining CA accumulation levels in the DV or by
interfering with the endogenous function of PfCRT (56). Studies
with the purified transporter will be necessary to confirm if PfCRT
itself serves as a drug target for CA.
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